| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 11, 2024 |
| Accession Number: | 0001193125-24-064465 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2024 | $23.00 | Outperform | Oppenheimer |
| 11/20/2023 | Outperform | TD Cowen | |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 11/11/2021 | $25.00 → $19.00 | Outperform | SVB Leerink |
| 9/28/2021 | $16.00 | Neutral → Buy | Citigroup |
| 8/6/2021 | $29.00 → $25.00 | Outperform | SVB Leerink |
Oppenheimer initiated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $23.00
TD Cowen initiated coverage of Harpoon Therapeutics with a rating of Outperform
Canaccord Genuity resumed coverage of Harpoon Therapeutics with a rating of Buy and set a new price target of $16.00
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients on treatment longer than a yearGenerally well-tolerated with a low incidence of cytokine release syndrome (CRS): Low-grade CRS in 29% of patients across highest step dose regimens; 95% of events occurred following first or second dose; no Grade 3 or higher CRS Dose and schedule optimization is ongoing; maximum tolerated dose not yet reached in step dose regimenManagement to host webcast and conference call to review
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update. The live call/webcast will take place at 4:30 p.m. ET / 3:30 p.m. CT / 1:30 p.m. PT on December 12, 2022 and can be accessed by dialing 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers with conference ID code number 13734677. A webcast of the l
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity seen at higher doses in both HPN217 and HPN328; low grade CRS manageable, no Grade 3 CRS reported Interim data from the ongoing Phase 1/2 trial of HPN217 presented at the 2021 ASH Conference reported clinical activity at higher dose levels, including an overall response rate (ORR) of 63% and a disease control rate (DCR) of 88% in the HPN217 2150 µg/week cohort with a manageable safety profileIn the ongoing Phase 1/2 trial for HPN328, 3 out of 4 patients with small cell lung cancer (SCLC) in the two highest d
SC 13G - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi
James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer. "I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy's promotion. I look forward to benefiting from Jim's extensive experience as we contin
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon. "We are pleased to welcome Haibo as Senior Vice President of Business Development at Harpoon," said Julie Eastland, President and CEO of Harpoon Therapeutics. "Haibo's extensive experience and strategic acumen will play a pivotal role in driving our business growth and forging impa
15-12G - Harpoon Therapeutics, Inc. (0001708493) (Filer)
EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
Oppenheimer analyst Hartaj Singh maintains Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Outperform.
4 analysts have expressed a variety of opinions on Harpoon Therapeutics (NASDAQ:HARP) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Harpoon Therapeutics, revealing an average target of $20.25, a high estimate of $23.00, and a low estimate of $12.00. This upward trend is appar
Merck & Co Inc’s (NYSE:MRK) fourth-quarter 2023 sales reached $14.63 billion, up 6% Y/Y, beating the consensus of $14.50 billion. Excluding Lagevrio and the impact of foreign exchange, growth was 14%. Pharmaceutical sales increased by 8% to $13.14 billion, driven by oncology, vaccines, and hospital acute care growth, partially offset by a decline in virology due to Lagevrio (COVID-19 treatment) and diabetes. Cancer drug Ketruda sales grew 21% to $6.61 billion. Lagevrio’s fourth-quarter sales declined 77% Y/Y to $193 million, and Gardasil/Gardasil sales grew 27% to $1.87 billion. Adjusted EPS came in at $0.03, down from $1.62 a year ago, surpassing the consensus loss of $(0.11), p
Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (NASDAQ:HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. "We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide," said Dr. Dean Y. Li, president, Merck Research Laboratories. "We are ple
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (NASDAQ:HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108498651/en/ "At Merck, we continue to enhance our onc